To date, there are only case reports that describe the benefit of PARP inhibitors in metastatic NSCLC, but these reports were in patients harboring a germline BRCA1/2 PV (Talreja et al. 2020; Zhang et al. 2021; Wu et al. 2022). This evidence concerns the gene BRCA1 and non-small cell lung carcinoma.